Chief Medical Officer

Oncology

Dr. Elizabeth G. Trehu, MD

Dr. Elizabeth G. Trehu is an expert in the field of Oncology. She went to NYU School of Medicine. Elizabeth Trehu is a published physician. She has 20 publications published. The most current publication "Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera."

Publications

Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 51...
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinic...
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in pa...
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.
Cost of screening for colorectal cancer: results of a community mass screening program and review of the literature.
Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist.
Possible myocardial toxicity associated with interleukin-4 therapy.

Schools

New York University
Georgetown University Hospital
Tufts UNe Med Center

Doctors Specialties

Hematology
Medical Oncology
Oncology

Accepted Insurances

Education

Tufts Medical Center
Georgetown University Hospital
NYU School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Anna Berkenblit, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Thomas Caughey, MD This Doctor is OpenDoctor Recommended.
	Dr. Matthew R. Kaufman, MD
	Dr. Austin Kim, MD This Doctor is OpenDoctor Recommended.
	Dr. Anne M. Yahanda, MD
	Dr. Sarah E. Slater, MD This Doctor is OpenDoctor Recommended.
	Dr. Erin R. Derose, MD This Doctor is OpenDoctor Recommended.
	Dr. Jared A. Gollob, MD This Doctor is OpenDoctor Recommended.
	Dr. Burt A. Adelman, MD
	Dr. Joseph Pearlberg, MD This Doctor is OpenDoctor Recommended.
	Dr. C D. Taylor, MD
	Dr. Michael J. Vasconcelles, MD This Doctor is OpenDoctor Recommended.
	Dr. Debashish Misra, MD This Doctor is OpenDoctor Recommended.
	Dr. Lisa B. Weissmann, MD This Doctor is OpenDoctor Recommended.